MA33598B1 - Nouvelles compositions de 1-[2-(2,4-diméthyl-phénylsulfanyl)-phényl]pipérazine - Google Patents

Nouvelles compositions de 1-[2-(2,4-diméthyl-phénylsulfanyl)-phényl]pipérazine

Info

Publication number
MA33598B1
MA33598B1 MA34709A MA34709A MA33598B1 MA 33598 B1 MA33598 B1 MA 33598B1 MA 34709 A MA34709 A MA 34709A MA 34709 A MA34709 A MA 34709A MA 33598 B1 MA33598 B1 MA 33598B1
Authority
MA
Morocco
Prior art keywords
phenylsulfane
phenylpiperazine
dimethyl
new formulations
formulations
Prior art date
Application number
MA34709A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Astrid-Maria Højer
Pernille Gundorf Drewes
Jens Kateb
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43628463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33598(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA33598B1 publication Critical patent/MA33598B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA34709A 2009-08-24 2012-03-21 Nouvelles compositions de 1-[2-(2,4-diméthyl-phénylsulfanyl)-phényl]pipérazine MA33598B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23622309P 2009-08-24 2009-08-24
DKPA200900950 2009-08-24
PCT/DK2010/050216 WO2011023194A2 (en) 2009-08-24 2010-08-23 New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine

Publications (1)

Publication Number Publication Date
MA33598B1 true MA33598B1 (fr) 2012-09-01

Family

ID=43628463

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34709A MA33598B1 (fr) 2009-08-24 2012-03-21 Nouvelles compositions de 1-[2-(2,4-diméthyl-phénylsulfanyl)-phényl]pipérazine

Country Status (32)

Country Link
US (3) US20120189697A1 (enExample)
EP (1) EP2470166B1 (enExample)
JP (1) JP2013502446A (enExample)
KR (1) KR20120065328A (enExample)
CN (1) CN102639117A (enExample)
AU (1) AU2010289022B2 (enExample)
BR (1) BR112012003280A2 (enExample)
CA (1) CA2769872A1 (enExample)
CL (1) CL2012000457A1 (enExample)
CO (1) CO6612204A2 (enExample)
CR (1) CR20120058A (enExample)
DK (1) DK2470166T3 (enExample)
DO (1) DOP2012000050A (enExample)
EA (1) EA021321B1 (enExample)
ES (1) ES2427628T3 (enExample)
GE (1) GEP20135950B (enExample)
HR (1) HRP20130819T1 (enExample)
IL (1) IL217914A0 (enExample)
MA (1) MA33598B1 (enExample)
ME (1) ME01602B (enExample)
MX (1) MX2012002199A (enExample)
NZ (1) NZ598083A (enExample)
PL (1) PL2470166T3 (enExample)
PT (1) PT2470166E (enExample)
RS (1) RS52959B (enExample)
SG (1) SG178325A1 (enExample)
SI (1) SI2470166T1 (enExample)
SM (1) SMT201300108B (enExample)
TN (1) TN2012000038A1 (enExample)
UA (1) UA105057C2 (enExample)
WO (1) WO2011023194A2 (enExample)
ZA (1) ZA201201360B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
JP5787881B2 (ja) 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
WO2011136376A1 (ja) * 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
EP3184104B1 (en) 2015-12-23 2018-09-12 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix
EP3184102A1 (en) 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
WO2018065348A1 (en) 2016-10-05 2018-04-12 Hexal Ag Novel enteric-coated tablet comprising vortioxetine
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN112006995A (zh) * 2020-08-14 2020-12-01 石药集团中奇制药技术（石家庄）有限公司 一种氢溴酸伏硫西汀片的制备方法
CN113350348B (zh) * 2020-11-05 2022-03-01 东南大学 一种1-二苯甲基-4-甲基哌嗪类化合物在制备保护肠道屏障完整性药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US6866146B2 (en) 2001-10-09 2005-03-15 Christian M. Heesch Protective case for string instruments
JP2008524332A (ja) * 2004-12-20 2008-07-10 コレジウム ファーマシューティカル， インク． 睡眠傷害のための医薬組成物
ES2493466T3 (es) * 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
JP5153629B2 (ja) * 2005-08-02 2013-02-27 ルピン・リミテッド 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
MY150647A (en) * 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
EP2470166A2 (en) 2012-07-04
BR112012003280A2 (pt) 2017-05-23
US20150150867A1 (en) 2015-06-04
RS52959B (sr) 2014-02-28
KR20120065328A (ko) 2012-06-20
EP2470166B1 (en) 2013-08-14
EA201290116A1 (ru) 2012-06-29
AU2010289022A1 (en) 2012-03-08
PL2470166T3 (pl) 2013-11-29
UA105057C2 (uk) 2014-04-10
US20160256398A1 (en) 2016-09-08
SG178325A1 (en) 2012-03-29
ES2427628T3 (es) 2013-10-31
CL2012000457A1 (es) 2013-01-25
CR20120058A (es) 2012-04-26
GEP20135950B (en) 2013-10-25
CN102639117A (zh) 2012-08-15
PT2470166E (pt) 2013-10-02
WO2011023194A2 (en) 2011-03-03
AU2010289022B2 (en) 2013-03-14
DOP2012000050A (es) 2012-07-31
SI2470166T1 (sl) 2014-03-31
MX2012002199A (es) 2012-03-16
ME01602B (me) 2014-09-20
IL217914A0 (en) 2012-03-29
ZA201201360B (en) 2013-05-29
US20120189697A1 (en) 2012-07-26
EA021321B1 (ru) 2015-05-29
TN2012000038A1 (en) 2013-09-19
SMT201300108B (it) 2013-11-08
CO6612204A2 (es) 2013-02-01
HRP20130819T1 (en) 2013-09-30
WO2011023194A3 (en) 2011-12-01
NZ598083A (en) 2013-08-30
CA2769872A1 (en) 2011-03-03
DK2470166T3 (da) 2013-09-08
JP2013502446A (ja) 2013-01-24

Similar Documents

Publication Publication Date Title
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
BR112015022861A2 (pt) inibidores de bromodomínio
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
BRPI0820308A8 (pt) composições farmacêuticas
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
EA201290116A1 (ru) Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
ECSP13012667A (es) Compuestos de triazolopiridina
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
MX2009011316A (es) Derivados del acido lipoico.
ECSP088532A (es) Formulación de suspensión de fexofenadina
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
EP2519512A4 (en) N1-ACYL-5-fluoropyrimidine derivatives
EP2394645A4 (en) MEDICAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVES OR SALTS THEREOF
UA97660C2 (ru) Жидкие композиции солей 4-[2-(4-метилфенилсульфанил)фенил]-пиперидина
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
FR2940976B1 (fr) Utilisation a des fins de criblage d'actifs anti-ages de formes solubles de la proteine de type desmogleine i
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases